about
In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica NanoconjugatesHydrogel containing dexamethasone-loaded nanocapsules for cutaneous administration: preparation, characterization, and in vitro drug release study.Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications.Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinicSolid lipid nanoparticles for ocular drug delivery.Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.Chemopreventive efficacy of naringenin-loaded nanoparticles in 7,12-dimethylbenz(a)anthracene induced experimental oral carcinogenesis.Effects in cigarette smoke stimulated bronchial epithelial cells of a corticosteroid entrapped into nanostructured lipid carriers.Natural Bioadhesive Biodegradable Nanoparticle-Based Topical Ophthalmic Formulations for Management of Glaucoma.Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT).The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicineNanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites.Nanoparticles in modern medicine: state of the art and future challenges.Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery.Challenges and advances in nanoparticle-based oral insulin delivery.Chitosan nanoparticles: a survey of preparation methods.Challenges in development of nanoparticle-based therapeutics.Intraperitoneal delivery of nanoparticles for cancer gene therapy.Impacts of nanomedicines in ocular pharmacotherapyNon-spherical micro- and nanoparticles: fabrication, characterization and drug delivery applications.Hierarchical layered double hydroxide nanocomposites: structure, synthesis and applications.Multifunctional nanomedicines: potentials and prospects.Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures.A review of biodegradable polymeric systems for oral insulin delivery.Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.Nanoencapsulation for drug deliveryHydrogels for central nervous system therapeutic strategies.From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS).Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.Preparation and characterization of gelatin nanoparticles containing pDNA encoding IL-12 and their expression in CT-26 carcinoma cells.Advanced materials for co-delivery of drugs and genes in cancer therapy.Toward an optimized treatment of intracellular bacterial infections: input of nanoparticulate drug delivery systems.Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer.Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells.In vitro and in vivo studies of lipid-based nanocarriers for oral N3-o-toluyl-fluorouracil delivery.Polymeric alginate nanoparticles containing the local anesthetic bupivacaine.Nondestructive rheological measurement of aqueous dispersions of solid lipid nanoparticles: effects of lipid types and concentrations on dispersion consistency.Multidentate zwitterionic chitosan oligosaccharide modified gold nanoparticles: stability, biocompatibility and cell interactions.Chitosan based mucoadhesive nanoparticles of ketoconazole for bioavailability enhancement: formulation, optimization, in vitro and ex vivo evaluation.
P2860
Q28828629-C4D4DC75-8CD6-46A4-B01E-E68BD5990C58Q33349360-155A5299-473B-41EF-ADE2-F209669F2C20Q33715708-A8B3E695-1A1B-469D-888E-E059E17FDE06Q33911056-7E8B07B1-8D34-45C1-9F51-E0FD8B2C675CQ34116807-A7D0D269-4C70-4ED5-ADED-D1B45255A9D8Q34265621-551CC556-589B-4FB0-8BD1-180DA2A9407FQ34509239-97017F40-9760-4BFC-9601-83E63ED58D63Q34768928-5C29BD4A-C2D1-41C0-8DBB-8EB0C7D047BCQ35691647-FA6C1CC7-E811-462F-8B21-72C33262CAA1Q36071814-4904891C-9FE6-4BE3-9C36-D2D7068AF541Q36126057-4112A04C-E188-41D1-B99F-02ED25DB70B8Q36403289-DD5C9897-6C98-491D-A28E-4A520C71776CQ36583732-8D99C874-861A-44ED-8F8D-0E6DAC98D831Q36920457-EFEADD3E-603A-4ABB-BBC6-31540AD10352Q37015849-56DE32F1-DF91-4AD8-878D-CA7A5F7EF310Q37632407-33661877-9EEA-46AD-BC7F-C93A7BB57999Q37980520-CECAE30E-9A6B-4408-B395-B31CC23A7868Q37992525-7BF4B763-22FF-4423-8564-657C8DDA711EQ38068493-D0470FE2-B3B2-440C-884E-4B5572FA3EFCQ38107200-364413B7-212F-40BA-A845-C6D5431E1D25Q38261278-44129FAD-B196-460A-AC5C-D5C5D2A192A9Q38308693-CA6AF4D9-FA4A-4873-BE02-1BE99C472B93Q38383487-F0FED9FB-67F9-414F-A858-81613910E427Q38401187-E1065BDD-7E4D-43E3-8F08-D59A227A28F7Q38525280-58AD102F-F1D8-49B1-84BE-6183571490C6Q38546964-73C2E341-8A9A-44F3-8EA3-F63C1249CB87Q38594967-F6B56A11-23EB-4CCD-B14F-195FB3261972Q38651258-172A8F8D-7873-4E19-8699-C089209C19D3Q38916539-ABBF4A26-5E16-4ED2-99D6-879B281DAD48Q38998571-35DB7899-C6B7-4742-97DB-FCED21C64FCEQ39117561-33324BF9-C488-4CE6-94B4-D35985628FE5Q39513734-4C114CC9-774A-4EE5-A4F4-2E8AB5358FA8Q40974806-A7E131D3-B24D-4867-A3A6-C5051FC5408BQ41929512-600DD838-C104-4D96-A31C-DE17B86EEBB0Q42059207-833A7036-3626-433D-B802-DD0893A0BFCDQ43101389-22319036-6FA9-447D-90ED-F5FB576EFFEBQ43145017-D175AE92-4B63-41F9-AB01-3DA14AC58639Q43149702-BA88FA69-D4CB-4BBD-9468-5DFDEC78615BQ45715043-A1AEFAA0-A75D-4ADC-A5C6-5904BAF6796DQ45800668-DA9648F2-CEDF-46AB-A4A8-C92CA9AFA4C1
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Nanomedicines for overcoming biological barriers.
@ast
Nanomedicines for overcoming biological barriers.
@en
type
label
Nanomedicines for overcoming biological barriers.
@ast
Nanomedicines for overcoming biological barriers.
@en
prefLabel
Nanomedicines for overcoming biological barriers.
@ast
Nanomedicines for overcoming biological barriers.
@en
P1476
Nanomedicines for overcoming biological barriers
@en
P2093
Maria José Alonso
P304
P356
10.1016/J.BIOPHA.2004.01.007
P577
2004-04-01T00:00:00Z